Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$41.88 USD

41.88
1,950,406

-0.87 (-2.04%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $41.90 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for EXAS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Exact Sciences Corporation [EXAS]

Reports for Purchase

Showing records 281 - 300 ( 366 total )

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 281

10/30/2012

Company Report

Pages: 9

3Q12 - Pivotal Top-Line Pushed Out

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 282

10/28/2012

Company Report

Pages: 8

3Q12 Preview - Expecting Management to Help Assuage Market Fears - Anticipating Better Clarity on Pivotal Data Timing - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 283

10/12/2012

Company Report

Pages: 9

Downgrading to NEUTRAL - Risk /Reward Unappealing

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 284

08/20/2012

Industry Report

Pages: 6

GAUGES IMPACT OF OBAMACARE TAX ON MEDICAL DEVICES COS.

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 285

07/26/2012

Company Report

Pages: 9

2Q12 Recap - Pivotal Trial Enrollment & Prevalence On Track - Expect Additional Validation Data in Oct

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 286

07/25/2012

Company Report

Pages: 5

Despite Larger Than Expected Q2 Loss

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 287

07/24/2012

Company Report

Pages: 8

2Q12 Preview - Anticipating a Quiet 2Q As Pivotal Study

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 288

07/24/2012

Company Report

Pages: 5

REITS - LOOKING FOR IN-LINE Q2

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 289

06/29/2012

Company Report

Pages: 3

We are placing Exact Sciences under review due to the departure from the firm of covering analyst

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 290

06/07/2012

Daily Note

Pages: 10

UPDATES BUY & HOLD

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 291

06/07/2012

Daily Note

Pages: 5

Termination of Coverage

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 292

06/07/2012

Daily Note

Pages: 8

What EXAS Owners Should Know About CPHD''s Proposed Colon Cancer Test - No Overlap with ColoGuard - Maintaining OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 293

06/06/2012

Company Report

Pages: 6

Clinical Trial Enrollment Nearly Complete - FDA Filing Next

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 294

05/29/2012

Company Report

Pages: 5

Reiterates Buy - Sigmoidoscopy Still Not The Answer... Cologuard Is!

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 295

05/22/2012

Industry Report

Pages: 4

Medical Devices: Pending Legislation Will Increase FDA''s Reach Offset By Some Benefits

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 296

05/02/2012

Company Report

Pages: 5

COLOGUARD DEEP-C TRIAL ON TRACK TO CONCLUDE ENROLLMENT IN Q3 - BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 297

05/02/2012

Company Report

Pages: 9

1Q12 Results In line - Selloff Related to Slightly Higher Burn

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 298

05/01/2012

Daily Note

Pages: 4

1Q12 Earnings Results

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 299

05/01/2012

Daily Note

Pages: 3

1Q12 Earnings Results

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 300

05/01/2012

Company Report

Pages: 5

1Q12 Results Review: Timelines on Track: Burn Goes Up Modestly

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party